Similar articles

• Eradication rate and adherence with high-dose amoxicillin and proton pump inhibitor as first-line treatment for Helicobacter pylori infection: Experience from University Hospital in Chile.

  von Muhlenbrock C, Cordova A, Nuñez P, Pacheco N, Herrera K, Quera R. von Muhlenbrock C, et al. Helicobacter. 2024 Jan-Feb;29(1):e13052. doi: 10.1111/hel.13052. Helicobacter. 2024. PMID: 38332683
• The cost effectiveness of Helicobacter pylori population screening-economic evaluation alongside a randomised controlled trial with 13-year follow-up.

  Høgh MB, Kronborg C, Hansen JM, Schaffalitzky de Muckadell OB. Høgh MB, et al. Aliment Pharmacol Ther. 2019 Apr;49(8):1013-1025. doi: 10.1111/apt.15193. Epub 2019 Mar 10. Aliment Pharmacol Ther. 2019. PMID: 30854700 Clinical Trial.
• Susceptibility-guided sequential strategy versus empirical therapy for Helicobacter pylori infection: study protocol for a randomised controlled trial.

  Lu K, Lang C, Zou X, Zang L, Sang W, Feng Q, Mu Y, Liu L, Xu C, Zhao J. Lu K, et al. Trials. 2023 Jun 19;24(1):413. doi: 10.1186/s13063-023-07457-z. Trials. 2023. PMID: 37337241 Free PMC article.
• Effectiveness and safety of vonoprazan-based regimen for Helicobacter pylori eradication: A meta-analysis of randomized clinical trials.

  Yang C, Li S, Huang T, Lin H, Jiang Z, He Y, Yuan J, An H. Yang C, et al. J Clin Pharm Ther. 2022 Jul;47(7):897-904. doi: 10.1111/jcpt.13637. Epub 2022 Mar 5. J Clin Pharm Ther. 2022. PMID: 35247003 Review.
• Helicobacterpylori eradication treatment for gastric carcinoma prevention in asymptomatic or dyspeptic adults: systematic review and Bayesian meta-analysis of randomised controlled trials.

  Terasawa T, Hamashima C, Kato K, Miyashiro I, Yoshikawa T, Takaku R, Nishida H. Terasawa T, et al. BMJ Open. 2019 Sep 20;9(9):e026002. doi: 10.1136/bmjopen-2018-026002. BMJ Open. 2019. PMID: 31542733 Free PMC article.